SK16722001A3 - Deriváty purínu, spôsob ich prípravy a farmaceutické kompozície tieto deriváty obsahujúce - Google Patents

Deriváty purínu, spôsob ich prípravy a farmaceutické kompozície tieto deriváty obsahujúce Download PDF

Info

Publication number
SK16722001A3
SK16722001A3 SK1672-2001A SK16722001A SK16722001A3 SK 16722001 A3 SK16722001 A3 SK 16722001A3 SK 16722001 A SK16722001 A SK 16722001A SK 16722001 A3 SK16722001 A3 SK 16722001A3
Authority
SK
Slovakia
Prior art keywords
radical
formula
radicals
phenyl
carbon atoms
Prior art date
Application number
SK1672-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Jean-Luc Haesslein
Original Assignee
Aventis Pharma S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S. A. filed Critical Aventis Pharma S. A.
Publication of SK16722001A3 publication Critical patent/SK16722001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1672-2001A 1999-05-21 2000-05-18 Deriváty purínu, spôsob ich prípravy a farmaceutické kompozície tieto deriváty obsahujúce SK16722001A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9906456A FR2793794B1 (fr) 1999-05-21 1999-05-21 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
PCT/FR2000/001335 WO2000071543A1 (fr) 1999-05-21 2000-05-18 Derives de la purine, leur procede de preparation, et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
SK16722001A3 true SK16722001A3 (sk) 2003-01-09

Family

ID=9545846

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1672-2001A SK16722001A3 (sk) 1999-05-21 2000-05-18 Deriváty purínu, spôsob ich prípravy a farmaceutické kompozície tieto deriváty obsahujúce

Country Status (33)

Country Link
US (2) US7122669B1 (https=)
EP (1) EP1183256B1 (https=)
JP (1) JP2003500407A (https=)
KR (1) KR100707895B1 (https=)
CN (1) CN1298719C (https=)
AP (1) AP1477A (https=)
AR (1) AR035317A1 (https=)
AT (1) ATE370951T1 (https=)
AU (1) AU4764500A (https=)
BR (1) BR0011282A (https=)
CA (1) CA2374714A1 (https=)
CZ (1) CZ20014163A3 (https=)
DE (1) DE60036102T2 (https=)
DK (1) DK1183256T3 (https=)
DZ (1) DZ3166A1 (https=)
EA (1) EA005072B1 (https=)
ES (1) ES2290033T3 (https=)
FR (1) FR2793794B1 (https=)
HU (1) HUP0201649A3 (https=)
IL (1) IL146441A0 (https=)
MA (1) MA26791A1 (https=)
MX (1) MXPA01011834A (https=)
NO (1) NO20015659L (https=)
NZ (1) NZ515556A (https=)
PL (1) PL352293A1 (https=)
PT (1) PT1183256E (https=)
SK (1) SK16722001A3 (https=)
TR (1) TR200103349T2 (https=)
TW (1) TWI284130B (https=)
UA (1) UA68441C2 (https=)
WO (1) WO2000071543A1 (https=)
YU (1) YU86601A (https=)
ZA (1) ZA200109602B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
AU3938802A (en) * 2000-10-31 2002-06-03 Aventis Pharma Inc Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6861524B2 (en) * 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
WO2004035132A2 (en) * 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US7951592B2 (en) * 2003-11-10 2011-05-31 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
CA2563123A1 (en) * 2004-04-02 2005-10-20 Adenosine Therapeutics, Llc Selective antagonists of a2a adenosine receptors
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
CN114149432B (zh) * 2016-09-30 2024-07-05 斯坦福国际研究院 用于癌症治疗的双重clk/cdk1抑制剂
CZ308029B6 (cs) * 2017-03-20 2019-11-06 Univerzita PalackĂ©ho v Olomouci 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky
JP2026500305A (ja) 2022-12-16 2026-01-06 アストラゼネカ・アクチエボラーグ ２，６，９三置換プリン

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
EP0841810B1 (en) * 1991-12-05 2000-06-21 Texas Instruments Incorporated Method to improve a video signal
CA2084222C (en) * 1991-12-06 2004-04-06 David R. Borcherding Novel trans cyclopentanyl purine analogs useful as immunosuppressants
BR9611157A (pt) * 1995-11-01 1999-03-30 Novartis Ag Derivados de purina e processos para sua preparação
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
CA2297967A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Also Published As

Publication number Publication date
CN1298719C (zh) 2007-02-07
PT1183256E (pt) 2007-11-13
JP2003500407A (ja) 2003-01-07
MXPA01011834A (es) 2002-04-17
EP1183256A1 (fr) 2002-03-06
KR20010113975A (ko) 2001-12-28
DE60036102D1 (de) 2007-10-04
IL146441A0 (en) 2002-07-25
CN1361780A (zh) 2002-07-31
FR2793794A1 (fr) 2000-11-24
ATE370951T1 (de) 2007-09-15
NZ515556A (en) 2003-08-29
CA2374714A1 (fr) 2000-11-30
DE60036102T2 (de) 2008-05-15
YU86601A (sh) 2005-07-19
US7122669B1 (en) 2006-10-17
EA005072B1 (ru) 2004-10-28
BR0011282A (pt) 2002-02-26
DZ3166A1 (fr) 2000-11-30
ES2290033T3 (es) 2008-02-16
NO20015659D0 (no) 2001-11-20
CZ20014163A3 (cs) 2002-10-16
AP1477A (en) 2005-10-19
US7208598B2 (en) 2007-04-24
US20050187228A1 (en) 2005-08-25
AU4764500A (en) 2000-12-12
AR035317A1 (es) 2004-05-12
EP1183256B1 (fr) 2007-08-22
HUP0201649A2 (en) 2002-08-28
WO2000071543A1 (fr) 2000-11-30
EA200101224A1 (ru) 2002-10-31
TR200103349T2 (tr) 2002-05-21
AP2001002355A0 (en) 2001-12-31
KR100707895B1 (ko) 2007-04-17
TWI284130B (en) 2007-07-21
MA26791A1 (fr) 2004-12-20
ZA200109602B (en) 2003-01-29
UA68441C2 (en) 2004-08-16
HUP0201649A3 (en) 2003-01-28
PL352293A1 (en) 2003-08-11
FR2793794B1 (fr) 2001-07-27
DK1183256T3 (da) 2007-12-03
NO20015659L (no) 2002-01-18

Similar Documents

Publication Publication Date Title
SK16722001A3 (sk) Deriváty purínu, spôsob ich prípravy a farmaceutické kompozície tieto deriváty obsahujúce
ES2458596T3 (es) Compuestos orgánicos
JP7646632B2 (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
CA2924206C (en) Pyrimidine fgfr4 inhibitors
TWI548621B (zh) 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
MX2007006821A (es) Derivados de 2,4 (4,6) pirimidina.
HUP0402504A2 (hu) Purinszármazékok, mint purinerg receptor antagonisták
TW202233620A (zh) Cftr調節劑化合物、組合物及其用途
ES2693545T3 (es) Compuestos agonistas de GPR142
JP2010526045A (ja) Ｃｄｃ２５ホスファターゼインヒビターとしてのトリアミノピリミジン誘導体
CN105153163A (zh) 2,9-二取代嘌呤-6-氨基异羟肟酸类组蛋白去乙酰化酶抑制剂及制备方法和应用
KR20180020119A (ko) 새로운 5형포스포디에스테라아제 억제제 및 그 용도
TW201536750A (zh) ３，５－二胺基吡唑激酶抑制劑之醫藥上可接受鹽
ES2965684T3 (es) Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
CA3025260C (en) Small molecule modulators of pantothenate kinases
CN121362190A (zh) 一种氮-(1-(9h-嘌呤-6-基)哌啶-4-基)苯甲酰胺类化合物、含其的药物组合物及其应用
AU2006202270A1 (en) Purine derivatives, preparation method and pharmaceutical compositions containing same
US20100173914A1 (en) Pharmaceuticals, compositions and methods of making and using the same
HK40017847A (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nsmase2) for the treatment of neurodegenerative diseases
HK40017847B (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nsmase2) for the treatment of neurodegenerative diseases